Pfizer Inc. (PFE)
Summary
Pfizer Stock Below 50-Day and 200-Day SMA: Buy the Dip or Exit Now?
PFE trades below key moving averages as investors weigh fading COVID sales against pipeline growth, acquisitions and a low valuation with a high dividend.
Stock Market Is Giving A Pristine Entry Point Into This 64-Year Dividend King
Johnson & Johnson (NYSE:JNJ | JNJ Price Prediction) and Pfizer (NYSE:PFE) both closed Q1 2026 with earnings beats, yet their post-report stories look nothing alike.
Is the Bearishness Around Pfizer and Gilead Sciences a Contrarian Opportunity?
Pfizer (NYSE:PFE | PFE Price Prediction) trades at $24.25, against a Wall Street consensus price target of $28.79, which represents implied upside of almost 19%.
Pfizer Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| TJD Thomas John Drogan PR Inc.IPAL SECURITIES Inc. | 122,982 | $3.37M | $3.04M | -$325,288.52 | -9.66% |
| DI David Izzi Brown, LISLE/CUMMINGS Inc. | 66,837 | $2.35M | $1.65M | -$696,235.8 | -29.63% |
| MSH Michelle S. Hickox FIRST FINANCIAL BANKSHARES Inc. | 433,584 | $12.23M | $10.72M | -$1.51M | -12.34% |
| TMB Timothy M. Bidwell Hazlett, BURT & WATSON Inc. | 10,223 | $501,439.16 | $252,865.9 | -$248,573.26 | -49.57% |
| LC Lisa Candera CIGNA INVESTMENTS Inc. /NEW | 54,038 | $1.74M | $1.34M | -$406,282.47 | -23.31% |
Pfizer Inc. Analysts
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Vamil Divan Guggenheim | 23,543.67 | $576,349.01 | $591,299.24 | $14,950.23 | 2.59% |
| EDS Evan David Seigerman BMO Capital | 1,361.66 | $33,333.33 | $34,163.94 | $830.61 | 2.49% |
Pfizer Inc. (PFE) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Pfizer Inc. ever had a stock split?
Pfizer Inc. Profile
| Pharmaceuticals Industry | Healthcare Sector | Albert Bourla CEO | NYSE Exchange | 717081103 CUSIP |
| US Country | 81,000 Employees | 24 Jul 2026 Last Dividend | 17 Nov 2020 Last Split | 13 Aug 2012 IPO Date |
Overview
Pfizer Inc. is a global biopharmaceutical company with a rich history dating back to 1849. Based in New York, New York, Pfizer has established itself as a leader in the discovery, development, manufacture, marketing, distribution, and sale of innovative biopharmaceutical products. Serving a wide range of therapeutic areas, Pfizer's portfolio includes medicines and vaccines that address a variety of health concerns, from cardiovascular metabolic conditions and infectious diseases to chronic immune and inflammatory diseases. The company has a significant global footprint, operating across the United States, Europe, and other international markets, catering to wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and more. Through strategic collaboration agreements with entities like Bristol-Myers Squibb Company, Astellas Pharma US, Inc., Merck KGaA, and BioNTech SE, Pfizer continues to lead in the development of medical breakthroughs for unmet medical needs.
Products and Services
- Eliquis, Nurtec ODT/Vydura, Zavzpret, and Premarin family brands: Targeting cardiovascular metabolic, migraine, and women's health, these products offer innovative treatments in their respective therapeutic areas.
- Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands: Focused on infectious diseases with unmet medical needs, including vaccines for various age groups and conditions.
- Comirnaty and Paxlovid brands: At the forefront of COVID-19 prevention and treatment, offering some of the earliest and most effective vaccines and antiviral treatments against the virus. Furthermore, Pfizer is exploring potential future mRNA and antiviral products.
- Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands: Offering biosimilars and original treatments for chronic immune and inflammatory diseases, showing Pfizer’s commitment to broadening access to critical medication.
- Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands: Addressing rare and severe conditions such as amyloidosis, hemophilia, endocrine diseases, and sickle cell disease with cutting-edge biopharmaceutical treatments.
- Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands: Including sterile injectable and anti-infective medicines that play a vital role in treating various infections and conditions.
- Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands: A comprehensive list of biologics, small molecules, immunotherapies, and biosimilars for treating cancer and other severe diseases, showcasing Pfizer’s extensive contribution to oncology and other advanced therapeutic areas.
- Contract Manufacturing: In addition to its extensive pharmaceutical product lineup, Pfizer is also involved in the contract manufacturing business, leveraging its vast infrastructure and expertise to produce medicines for other entities.
